Home / business / Jubilant Life Sciences Shares Jump Five Percent on Gilead Pact for Covid-19 Therapy Drug

Jubilant Life Sciences Shares Jump Five Percent on Gilead Pact for Covid-19 Therapy Drug

-
The Gilead pact signed between Jubilant Life Sciences' subsidiary Jubilant Generics Ltd and Gilead, will grant the former the right to register, manufacture and sell the latter's investigation drug, remdesivir - a potential therapy for Covid-19.

from Top Business News- News18.com
Read The Rest:timesnownews...
Jubilant Life Sciences Shares Jump Five Percent on Gilead Pact for Covid-19 Therapy Drug Jubilant Life Sciences Shares Jump Five Percent on Gilead Pact for Covid-19 Therapy Drug Reviewed by Team Exprssnews on May 13, 2020 Rating: 5

No comments:

Subscribe to: Post Comments ( Atom )
Powered by Blogger.

SIGN UP & STAY UPDATED


Subscribe to our newsletters now and stay
up-to-date with exclusive offers.